Výsledky vyhledávání

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study)

Publikováno v: Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Background Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2eb49abcc7614d4a358430c300f92e6

Zobrazit plný text záznamu

Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer

Autor: Eduardo Richardet, Teena M. West, Gilberto Schwartsmann, Belinda J. Hall, José Rodrigues Pereira, Auro del Giglio, C. Blajman, Luis Fein, Mauro Orlando, Maximiliano Van Kooten

Publikováno v: Lung Cancer. 58:80-87

Previous studies have indicated that, in combination with cisplatin, fixed dose rate gemcitabine may be more efficacious than standard infusion gemcitabine. This open-label, randomised phase II study was aimed to compare the efficacy and safety of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4848d3b49535d8ad6508d6ba9cb07810
https://doi.org/10.1016/j.lungcan.2007.05.004

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients

Publikováno v: European Journal of Cancer. 37:1006-1013

The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with daily×5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3421449c8ef7b9ad98f3044433ed6a2d
https://doi.org/10.1016/s0959-8049(01)00080-6

Zobrazit plný text záznamu

Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer

Autor: R. Kneitschel, E. Aman, C. Blajman, A. Fiorini, C. Milano, S. Carraro, A. Jarentchuk, M. Barugel, J. Nadal, E. Roca, G. Gonzalez, R. Giglio, M. Sardi, E. Pennella, M.T. Santarelli, A. Navigante

Publikováno v: European Journal of Cancer. 32:429-432

From January 1990 to April 1993, 60 oesophageal cancer patients were enrolled in a protocol of non-surgical treatment that consisted of induction chemotherapy followed by concurrent chemoradiotherapy. Induction chemotherapy consisted of cisplatin 40

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ad3168ac7df9dfdd27aaa3147198946
https://doi.org/10.1016/0959-8049(95)00524-2

Zobrazit plný text záznamu

A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

Autor: C, Blajman, L, Balbiani, J, Block, F, Coppola, R, Chacon, L, Fein, S, Bonicatto, A, Alvarez, A, Schmilovich, F M, Delgado

Publikováno v: Cancer. 85(5)

A prospective, multicenter, randomized, Phase III trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) with a combination of vinorelbine and doxorubicin (NA) in the treatment of patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b7ea6febe84156bd80b604a3a07d06a8
https://pubmed.ncbi.nlm.nih.gov/10091793

Zobrazit plný text záznamu

Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group

Publikováno v: Seminars in oncology. 24(5 Suppl 15)

Paclitaxel (Taxol; Bristol-Myers Squibb Company; Princeton, NJ) is an antineoplastic agent that inhibits microtubular function and has shown efficacy in several solid tumors, mainly ovarian tumors, in which 20% to 40% response rates in previously tre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::85cdf627a9f23903db9dae272df59d54
https://pubmed.ncbi.nlm.nih.gov/9346223

Zobrazit plný text záznamu

Tolerability and incidence of infusion site reactions with emulsion formulation of vinorelbine (ANX-530) compared to vinorelbine solution

Autor: G. Arroyo, P. Quintana, L. Arboit, Luis Fein, J. M. Robbins, L. P. Lopez, J. Schupp, H. Requejo, C. Blajman, M. Chacón

Publikováno v: Journal of Clinical Oncology. 26:13549-13549

13549 Background: ANX-530 is an oil-in-water emulsion formulation of vinorelbine that has demonstrated less vein irritation, equivalent antitumor activity, and similar pharmacokinetic profiles to v...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22f4a60cfb41e459983eaebbf6c346f4
https://doi.org/10.1200/jco.2008.26.15_suppl.13549

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání